Catabasis Pharmaceuticals Inc (NASDAQ:CATB) – Research analysts at Wedbush lowered their FY2022 EPS estimates for shares of Catabasis Pharmaceuticals in a report released on Tuesday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings of $0.61 per share for the year, down from their previous forecast of $0.71. Wedbush currently has a “Outperform” rating and a $6.00 target price on the stock.
Catabasis Pharmaceuticals (NASDAQ:CATB) last released its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.07. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.25 million.
CATB stock traded down $0.11 during trading hours on Wednesday, reaching $1.92. The company’s stock had a trading volume of 394,145 shares, compared to its average volume of 1,057,294. Catabasis Pharmaceuticals has a twelve month low of $1.09 and a twelve month high of $3.78. The company has a market capitalization of $59.52, a price-to-earnings ratio of -1.58 and a beta of 0.80.
Institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its position in shares of Catabasis Pharmaceuticals by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 49,000 shares in the last quarter. Deutsche Bank AG purchased a new position in shares of Catabasis Pharmaceuticals in the fourth quarter valued at about $335,000. Renaissance Technologies LLC lifted its position in shares of Catabasis Pharmaceuticals by 167.2% in the fourth quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock valued at $698,000 after acquiring an additional 293,300 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Catabasis Pharmaceuticals by 146.1% in the fourth quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 45,476 shares in the last quarter. Institutional investors and hedge funds own 34.39% of the company’s stock.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.